Table 4. Univariate and multivariate analysis of 117 patients with an EGFR-activating mutation who received EGFR TKI therapy.

	N	Events	Univariate			Multivariate
			OS (month)	95% CI	p	p	HR (95% CI)
Age
≤65	93	62	24.4	19.743–29.057	0.992
>65	24	15	19.6	3.851–35.349
Gender
Male	46	32	23.6	15.857–31.343	0.290
Female	71	45	24.5	14.740–34.260
Smoking status
Non-smoking	84	56	24.3	17.741–30.859	0.844
Smoking	33	21	25.8	16.049–35.551
PS score
0–1	109	71	24.4	17.741–31.059	0.294
≥ 2	8	6	8.1	0.0–24.454
Histological type
Adenocarcinoma	113	73	24.5	17.538–31.462	<0.001	<0.001	11.984 (3.873–37.082)
Squamous	4	4	7.3	3.870–10.730
Disease type
Recurrent disease	30	17	38.0	20.526–55.474	0.093
Local or metastatic disease	87	60	21.6	16.819–26.381
Mutation type*
19 Del	58	38	24.5	20.524–28.476	0.519
L858R	47	32	21.6	7.620–35.580
Line of TKI therapy#
First line	65	37	19.6	13.213–25.987	0.903
Second line	42	33	24.4	19.243–29.557

P values were listed in the Table. *4 patients with exon 18 mutations, 5 patients with a L861Q mutation, and 3 patients with other types were not enrolled. ^#7 patients with third-line TKIs, 1 patient with fourth-line TKIs, and 2 with other lines were not enrolled.